本帖最后由 maicon08 于 2023-4-28 15:12 编辑
: i. D; y! O9 e4 o8 C/ s8 ~, j; X2 I, W5 h) F) q
一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。6 R3 s, \) q; r+ R+ v
6 J& A2 ~( y T; O0 Y# F4 {: Z* r
https://www.163.com/dy/article/I3BTTPRD053438SI.html
( V: p6 O# W, ?
* V. C8 B# l# g1 S; X9 z1 e: B( r5 ^8 N/ g; `7 G+ y5 j1 a
在研疗法-免疫治疗
- H G: L6 w9 IDevelopmental Therapeutics—Immunotherapy- X& r# A' u9 K+ F
. f3 `& n; R) {4 l, E
摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心 + F7 T# F& {" u! s( k1 y# j8 O
在研疗法-分子靶向药物和肿瘤生物学
9 R- H7 e }: N, H Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology . i3 f6 L. B2 Q, T
摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心
' h- |% L! Z7 r6 p& [8 L* c Y
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院
( p! W8 G) E6 D k( ~
胃肠道肿瘤-结直肠癌和肛门癌
# I- P3 G4 ~( x& O ^ Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院
3 l. G! V6 t& X
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
# D* A _1 G/ y9 N, [5 v摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心 7 F2 r. K$ w% L' ^5 T0 Y
妇科肿瘤 Gynecologic Cancer
6 K9 R/ d; l% c& X5 q摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院 5 Q. ^& Z% b( E1 m8 ~
头颈肿瘤
4 P* V/ R, o$ B6 R. X+ S Head and Neck Cancer
5 {; z, t: {+ c) z# Q S& P" G摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心 * \+ I1 y: t; {
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心 ' L6 D* h- o1 L. a4 q
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心 ; ~4 {/ C; ?5 t$ ^ L- F! T) \
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia * ^% s' y( k* L0 X% ]
摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心
% o# Q O& X6 t4 j7 {
血液系统恶性肿瘤-浆细胞疾病6 {% C, @5 C- S4 ~. I! g3 E. j
Hematologic Malignancies—Plasma Cell Dyscrasia
0 B* G/ @ g S, A2 S摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院 9 `8 _* v3 l7 S" }* A; W0 Z
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤
5 F7 h! ?' o3 J8 R. {6 @4 s% M/ X Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers ! n5 h- m9 {3 ?. K& H" ?2 n1 ]& O0 s
摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院 2 e3 D: \ J/ o4 W) \
肺癌-转移性非小细胞肺癌1 T. Y2 H2 l( E9 v G5 K
Lung Cancer—Non-Small Cell Metastatic
7 l4 ]5 O5 d6 d/ h3 x) e摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院
& `. @' t; i% a- B/ Z, o r* @
& I+ x# J- A+ \. W. e2 |
摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院
) V& q5 \" G. _- ]1 v
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院
: A2 Y! v7 i* O% v7 ~
黑色素瘤/皮肤癌
' N! v e' n3 I! H Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院 + D- ]( c+ t% W! l* f! C9 ?
快速摘要报告
/ B0 A5 Y7 P7 P! p2 @ Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心
D1 b9 R; Y1 G( B1 [' a
临床科学研讨会/ ?+ M: m1 _, {( t |6 e' k
Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院
* D1 T/ j c2 Q, R) ^& I
8 P% g3 I) E* w' ~0 h' G | 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
发表于 2023-4-28 20:42:18
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
